Lenker April, Mayer Deborah K, Bernard Stephen A
Rex Hematology Oncology Associates in Raleigh, NC.
University of North Carolina at Chapel Hill.
Clin J Oncol Nurs. 2015 Oct;19(5):501-4. doi: 10.1188/15.CJON.501-504.
Malignant pleural effusions (MPEs) are common complications that occur with advanced stages of cancer. In general, they indicate a poor prognosis and greatly affect quality of life (QOL). The treatment goal of MPEs is to provide relief of symptoms. The standard treatment for MPEs is talc pleurodesis; however, indwelling pleural catheters have become more frequently used. This article focuses on current management strategies for MPEs and assesses their influence on QOL.At a GlanceSymptoms of malignant pleural effusions (MPEs), which involve the accumulation of fluid in the pleural space, include dyspnea, shortness of breath, chest pain, and other issues that decrease functional status.Treatment for MPEs should be palliative, achieving immediate symptom relief and improved quality of life.The optimal treatment strategy for MPEs should have minimal side effects, require minimal or no hospitalization, and have low rates of recurrence.
恶性胸腔积液（MPEs）是癌症晚期常见的并发症。一般来说，它们预示着预后不良，并极大地影响生活质量（QOL）。MPEs的治疗目标是缓解症状。MPEs的标准治疗方法是滑石粉胸膜固定术；然而，留置胸腔导管的使用频率越来越高。本文重点关注MPEs的当前管理策略，并评估它们对生活质量的影响。
一目了然
恶性胸腔积液（MPEs）的症状包括胸腔积液积聚，如呼吸困难、呼吸急促、胸痛以及其他降低功能状态的问题。
MPEs的治疗应是姑息性的，实现立即缓解症状并改善生活质量。
MPEs的最佳治疗策略应具有最小的副作用，需要最少或无需住院治疗，且复发率低。
